Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07142954
PHASE3

Epidemiology and Biomarker Study in Alzheimer's Disease

Sponsor: Eli Lilly and Company

View on ClinicalTrials.gov

Summary

Study AACU determines rates of cognitive worsening in participants within elevated and not elevated plasma P-tau217 cohorts. Participation in AACU will last approximately 7 years.

Official title: A Longitudinal, Prospective Epidemiology Study in Alzheimer's Disease: Assessing Neurocognitive and Biomarker Changes and Health Outcomes in Individuals at Risk for Symptoms of Alzheimer's Disease (ANCHOR-AD)

Key Details

Gender

All

Age Range

55 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

3400

Start Date

2025-08-25

Completion Date

2033-07

Last Updated

2026-02-10

Healthy Volunteers

Yes

Interventions

OTHER

P-tau217 Test

A plasma test measuring phosphorylated tau at Position 217 (P-tau217).

Locations (3)

Care Access - Houston

Houston, Texas, United States

The University of Tokyo Hospital

Bunkyō City, Japan

Souseikai Sumida Hospital

Tokyo, Japan